Diagnosis and Management of Community-Acquired Pneumonia in Hospitalized Patients

Welcome back to The Deep Dive. Today we're tackling a really core topic. Community acquired pneumonia and adults who end up hospitalized. It's something we manage all the time, but you know, the landscape keeps changing new bugs, different resistance patterns. So this deep dive is aimed right at practitioners like you, looking for a practical synthesis. We're drawing from recent big reviews, ENJM, JAMA, the Etzetsa guidelines. Our goal here is to really integrate these updates into how you approach these patients day to day. Absolutely, and it's essential because EAP, I mean, it's still a huge driver of illness and unfortunately mortality, especially once someone needs admission, we constantly have to refine how we think about it, you know, move past some older assumptions and really use the latest data on what's causing it and how to treat it. There's just so much new information, especially around viruses and drug resistance that a focused update like this is, well, it's timely. Okay, let's get into it. Starting right at the beginning. Defining CAP when a patient is admitted. So diagnostically, the cornerstone is finding a new infiltrate on imaging, right? Chest X, right, or CT. Exactly. And it's not just finding something incidentally. It has to line up with the clinical picture, the symptoms and signs we see. Things like cough, fever, maybe some crackles on exam. Right, or even confusion, especially in older folks, that new infiltrate plus compatible symptoms, that's your entry point for a CFP diagnosis in the hospital. So once we're pretty sure at CAP, the very next step is figuring out how sick the patient is, essentially deciding where they need to be treated, floor ICU. That's critical. It really is. That site of care decision dictates, well, pretty much everything that follows monitoring how aggressive we are with initial antibiotics. And yeah, we rely heavily on validated tools for this. We used to talk a lot about CIB 65, maybe because it's simpler, but the guidelines now really push for something more comprehensive, the pneumonia severity index, the PSI. Why the shift towards PSI? Well, the PSI, it is definitely more complex involves 20 different factors. Yeah. But its strength lies in its negative predictive value. It's really good at identifying those truly low risk patients, class I and two folks, who probably don't need to be admitted at all. So it helps avoid unnecessary hospitalizations. Precisely. But, and this is a huge but, the guidelines emphasize, you absolutely cannot rely solely on the score. Clinical judgment is paramount. That makes sense. So what are those things, those non-numerical factors that make you say, okay, this PSI score is low, but this patient still needs to come in? It often comes down to the patient's overall situation. Yeah. Think about someone with a low score, but maybe they have really poorly controlled heart failure, or significant liver disease, or they're on dialysis, or maybe their functional status is very poor. They have dementia, or significant substance use issues, especially alcohol. These things dramatically increase the risk of them decompensating, regardless of the initial PSI number. And social factors too, I imagine. Absolutely critical. Homelessness, or just the inability to reliably get meds or make it to follow up appointments. Those are definite reasons to admit, if the score looks okay, safety net issues. Okay, so we've decided admission is necessary. Now we need to gauge the severity more formally, which really impacts our initial antibiotic choices, especially thinking about ICU level care. How do the ATS IDSA criteria help define severe CAP? Right here, the focus shifts specifically to looking for organ dysfunction or signs of impending failure. It boils down to having either one major criterion or three or more minor ones. Major criteria being the really obvious one. Exactly, needing mechanical ventilation, or being in septic shock, needing vasopressors. Those are straight forward ICU triggers. But the minor criteria are maybe more subtle. They are, and crucial to catch early. Things like a high respiratory rate over 30 breaths per minute. Euremia, so BUN over 20. Lecopenia, low white count, hypothermia, confusion, or seeing infiltrates in multiple lobes on the X-ray. If you tell you up three or more of those minor criteria, that patient meets the definition for severe CAP and generally warrants ICU admission, and importantly, broader initial antibiotic coverage. Got it. So, that severity assessment directly links to the treatment plan. Let's pivot now to why those treatment plans are changing. It's all about the evolving bugs, the etiology, the recent studies, like those in NEJM, show a really profound shift in the last decade or so. Our old assumptions about what causes CAP might not hold up anymore. It's fascinating and honestly a bit humbling. The first major point is just how often we don't find the specific cause. Despite all our fancy tests, PCR panels, cultures, we only nail down a definitive pathogen in maybe 38 to 40% of hospitalized cases. That's really low, so most of the time we're essentially treating empirically based on the syndrome. Pretty much. We're flying blind a lot of the time. Yeah. Which is exactly why our initial empirical therapy has to be broad and started quickly. Okay. We have to accept that CAP is often clinical diagnosis first and foremost. And when we do identify pathogen, the story has changed. It's not always bacteria anymore. Is it? There's this significant viral shift. Huge shift. Respiratory viruses are now the most commonly detected pathogens in many studies. We're talking up to 40% of identified causes in some recent cohorts. Which specific viruses are we seeing most often? Well, surprisingly, perhaps human rhinovirus leads a pack in some big US studies, maybe around 9% of cases. Influenza A and B are right behind and maybe 6% combined. Rhinovirus, the common cold virus, causing pneumonia bad enough for hospitalization. It seems so, yes. And while we don't have a specific antiviral for rhino, its prevalence tells us something important. A big chunk of what we label CAP might be primarily viral. This really underscores the need for good antibiotic stewardship down the line. Okay. So that viral dominance has immediate practical implications for testing, right? Absolutely. There's a clear mandate now. During flu season or when COVID is circulating, every hospitalized patient with CAP needs testing for both influenza and COVID-19. And why is this so critical? Well, several reasons. If influenza is positive, you need to start a cell temavir ideally within 48 hours. If it's COVID, specific treatments like Pax-Lovid or Bremdesivir might be indicated depending on the patient. And crucially, knowing the viral diagnosis directly impacts infection control, you need to isolate these patients appropriately to prevent spread on the wards. So let's say the test comes back positive for flu. Can we just stop the antibiotics right there? The sources seem cautious about that, especially if the patient is quite sick. Yeah, you have to be really careful there. That brings us to the problem of co-infection. Bacterial superinfection on top of a viral pneumonia is surprisingly common. How common are we talking? Overall, maybe 3 to 15 percent of all CLIACI cases have both a virus and bacteria identified. But if you look specifically at patients with confirmed viral pneumonia, especially influenza, the rate of secondary bacterial infection can shoot up dramatically, maybe as high as 40 percent in some studies, often early in the admission. Why is influenza so bad for that? Influenza damages the respiratory lining, the mucosa. It basically creates an open door for bacteria like Staffa Rias or Strapnumo to invade secondarily. So the bottom line is, even if a rapid viral test is positive, you generally need to continue the initial empirical bacterial coverage, at least initially. Exactly. Until that patient is clearly stabilizing, improving clinically, maybe inflammatory markers are coming down, finding a virus explains part of the story, but it doesn't mean you can ignore the risk of a concurrent bacterial infection, especially in severe cases. Okay, let's shift back to the bacteria then. Viruses are up, but the classic bacterial culprits haven't vanished, though their roles seem to be changing too. That's right, Streptococcus pneumonia pneumococcus is still considered the number one bacterial cause, but its frequency has dropped quite a bit. We're now detecting it in only about 5 to 15 percent of hospitalized CKP cases in the US. And that decline is largely due to vaccination, plain and simple. Wide spread use of the pneumococcal conjugate vaccines, the PCV series, has been incredibly successful in reducing disease caused by the serotypes included in the vaccine. It's a major public health win. But still, since it's the leading bacterial cause, it remains the primary target for our standard beta-lactin antibiotics. What other bacteria are still relevant enough to influence our standard impure choices? We definitely need to cover hemophilus influenza. It pops up in maybe up to 16 percent of cases in some series, particularly common in smokers or people with underlying lung damage. And Streptococcusorius, including MRSA, is always a concern, especially as we mentioned, as that secondary infection after influenza. You need a high index of suspicion there. And then there are specific patient groups where we worry more about certain gram negatives. Right. Patients with structural lung disease like bronchiectasis or severe COPD, who are maybe on frequent steroids. In those folks, you have to think about edrobactralis, things like clip, seal, and pneumonia, or more axilla catarollis. These might require broader initial coverage than you'd use for uncomplicated CAP, leaning towards agents like Ceptriaxone, or ampacillin-silbactum right off the bat. And lastly, completing the picture, we have the atypicals, Michael Plasma, Chlamydia, Legionella, the ones that historically drove the use of macrolides or fluorokinolones. They're still in the mix, for sure, but probably account for a smaller slice of the pie overall, maybe somewhere in the 3-11 percent range combined. But because they can look clinically similar to typical bacterial pneumonia, and importantly, they don't respond to beta lactams, we still need to make sure our initial empiric regimen covers them for essentially all hospitalized patients, which leads us nicely into management strategies. Exactly. Section three, empirical management, speed is key. Right. Getting antibiotic started promptly. For the average hospitalized adult, no specific MDR risk factors, what's the go-to standard regimen according to the latest guidelines? This standard strongly recommended approach is combination therapy, specifically a beta-lactam antibiotic, plus a second agent. And the preferred combination is usually a beta-lactam like Ceptriaxone or ampacillin-silbactum, if you're worried about anaerobes 2, plus a macrolide, most commonly is atheramysin. Doxycycline is listed as an alternative to the macrolide. Why the emphasis on combination therapy? Why not just use one broad spectrum drug? It's all about ensuring reliable coverage for the most likely pathogens right at the start. The beta-lactam hits strep pneumo and H-flu very well. The macrolide or doxycycline covers the atypical pathogens, microplasma, chlamydia, legionella, so the combination covers the basis. Let's drill down on that macrolide component, atheramysin specifically. You said atypicals are only maybe 3-11% of cases, so why is adding atheramysin so strongly recommended even if you don't strongly suspect an atypical? Is it purely for that coverage? This is actually a really key point and the thinking has evolved. While atypical coverage is part of it, there's growing evidence, particularly from observational studies in severe CKP, that using a macrolide in combination actually improves outcomes, including reducing mortality, potentially beyond just its effect on atypical bacteria. Ah, so this is the macrolide edge or the immunomodulatory effect people talk about? Exactly that. As atheramysin isn't just an antibiotic, it also seems to have significant anti-inflammatory properties. Can you elaborate on that mechanism? What's it doing besides killing bacteria? It appears to dampen down the excessive inflammatory response, that can cause so much damage in severe pneumonia, the cytokine storm, essentially. It's been shown to reduce levels of key pro-inflammatory cytokines, like IL-6 and TNF alpha, it might even interfere with some bacterial virulence factors. So it's thought to modify the host's own harmful response, which makes it a valuable partner to the beta-lactam that's focused purely on killing the bacteria. That's fascinating. So given that potential immunomodulatory benefit with isytheramysin, how should we view doxycycline the alternative? Does it offer the same advantage? Doxycycline is definitely a good alternative for providing the necessary atypical coverage. It's great if someone has a prolonged QTC interval or drug interactions that make macrolides risky. However, the evidence for doxycycline having similar potent immunomodulatory effects in CPAP is much weaker compared to zytheramysin. So while you maintain the antimicrobial spectrum, you might be giving up some of that potential host response benefit when you choose doxy over zythro. It's a trade-off to consider based on the patient. Okay, what about floor quinolems then? Drugs like lemafloxicin or moxifloxicin, they cover atypicals, some gram negatives. Seems like effective monotherapy. Why are they generally reserved? They are reserved really only for patients who have a compelling reason they can't take both a beta-lactam, like a severe penicillin allergy, and a macrolide or doxycycline. The guidelines or reviews consistently urge caution because floor quinolems come with a higher risk profile for certain adverse events. We worry about C-difficial infections, QTC prolongation and arrhythmias, tendon issues, eortic dissection, a range of potential problems. Given that the standard combination therapy is generally safe and effective, floor quinolemonotherapy is usually held back unless absolutely necessary. Makes sense. Now, let's shift gears to sicker patients or those with specific risk factors where we need to worry about multi-drug resistant organisms, specifically MRSA and pseudomonas. Screening for these risks seems non-negotiable, especially in severe CAP. Absolutely non-negotiable. Before you even write that first antibiotic order for someone with severe CAP or even moderate CQ with risk factors, you have to actively screen. What are the key risk factors we're looking for for MRSA? You're asking about prior MRSA infection or colonization obviously, but also recent hospitalization, especially if they received IV antibiotics within the last 90 days. Or sometimes after severe influenza, there's a higher risk of secondary MRSA pneumonia. And for pseudomonas? Think structural lung disease bronchiactases is a big one. Severe COPD, particularly if they need frequent steroid bursts or are on chronic steroids for another reason. Prior pseudomonas isolation is also key. Reason broads spectrum antibiotic use. So if these risk factors are present or if the patient lands in the ICU with septic shock or needing ventilation, we have to broaden coverage immediately. What do we add for empiric MRSA coverage? You add either vancomycin or linozol into your baseline regimen. The choice between them might depend on things like kidney function lines all it is easier on the kidneys or concern for MRSA backteremia where vancomycin sometimes be preferred initially. And for covering pseudomonas? You need an anti-seudomonal beta-lactam. That usually means Pipercil and Tuzobactam, Zosin, Zafipime, Zeptazidium, or sometimes a carbopinam like meripinam or amyipinam, especially if you suspect other resistant gram negatives too. And for those really sick ICU patients, say with shock or on the ventilator. For them, the standard recommendation is to empirically cover both MRSA and pseudomonas right from the start while you wait for cultural results. The risk of missing one of these in a critically ill patient is just too high. No, speaking of covering both, you often end up using vancomycin plus Pipercil and Tuzobactam, but there's a significant warning about that specific combination, right? Yes, a very important clinical pearl emphasized in recent reviews. Combining vancomycin and Pipercil and Tuzobactam is associated with a significantly increased risk of acute kidney injury, A.K.I. How significant is that risk? It appears quite substantial, especially in critically ill patients who often have other risk factors for A.K.I., like volume depletion or exposure to contrast eye. The mechanism isn't fully clear, but the association is strong enough that we need to be mindful. So what's the practical implication? Should we avoid that combo altogether? Not necessarily avoid it completely, but definitely use it with caution and increased vigilance for A.K.I. If possible, especially in high risk patients in the ICU, consider alternatives. Maybe use lines all of them instead of vancomycin for MRSA coverage if appropriate, or use cephopime instead of piptozo for pseudomonas coverage if the spectrum fits. It's about minimizing that synergistic nephrotoxicity when feasible. Okay, good point. Let's talk about some other tools and strategies. Microbiologic testing who actually needs the full workup with blood cultures, sputum, legionella, urine, antigen, etc. The guidelines are pretty clear now. Reserve the extensive microbiologic workup, primarily for patients with severe CAP. The ones meeting those ICU criteria, or those who have specific risk factors for MRSA or pseudomonas, where identifying the bug is crucial for targeted therapy. For patients with non-severe CAP admitted to the regular floor, the yield of routine blood cultures and sputum cultures is actually very low, and they rarely change management. So being selected makes sense from a resource and cost perspective. What about pro-calcitonin? It's used a lot, but it seems controversial. Where does it fit in CAT management? Pro-calcitonin is, well, it's a tool with potential but definite limitations. Its main purported utility is helping to differentiate bacterial from viral pneumonia, which could theoretically guide antibiotic stewardship. How so? A very low pro-calcitonin level, say less than 0.1 or 0.25 micrograms per liter, might suggest a viral infection is more likely, or that a bacterial infection, if present, is less severe systemically. This might support a decision to stop antibiotics earlier, maybe after 48-72 hours, if the patient is clinically stable. But what are the paviyats? Why isn't it a perfect test? Big paviyats. It can be falsely low early in infection, or with atypical pathogens like microplasma, and it can be falsely high in many non-infectious inflammatory conditions. Major trauma, surgery, pancreatitis, kidney failure. Critically, it should never be used as the sole reason to withhold antibiotics from a patient who looks clinically septic or has clear signs of pneumonia. Its main value, if used, is often in supporting antibiotic deescalation or cessation in stable patients, not initial decision-making. Okay. What about adding steroids? Ajunctive corticosteroids for CAP? Is that standard now? Definitely not standard for everyone. This is still an area where the decision needs to be highly individualized. The best evidence suggests potential more tally benefit only in patients with severe CIP. So only the sickest patients, the ones in the ICU, perhaps? Generally, yes. Specifically those who meet the severe CIP criteria, maybe particularly those with refractory shock or very high inflammatory markers. And the benefit seems greatest if steroids are started early within the first 24 hours or so. Are there downsides? Of course. Hyperglycemia is common and needs management. There might be a slightly increased risk of things like GI bleeding, or maybe secondary infections, although the mortality data in severe CAPE seems to favor steroids, despite these risks. But for non-severe CIPE, the risks generally outweigh any potential benefit. And it's important to distinguish this from using steroids in COVID-19 pneumonia, right? Absolutely crucial distinction. Using Dexamethasone in patients hospitalized with COVID-19, requiring oxygen is standard of care based on specific trials like recovery. That's aimed at the specific immunopathology of SARS-CoV-2 lung injury. The discussion around steroids in non-COVID CAPE is based on different studies and likely different mechanisms, focused more on mitigating the systemic inflammatory response and shock in presumed bacterial severe pneumonia. Don't conflate the two indications. Good clarification. Lastly on management, let's talk about getting patients better and out the door, transitioning to oral antibiotics and duration of therapy. The key is clinical stability. Once the patient meets criteria like temperature consistently below 37.8 degrees C, heart rate under 100, respiratory rate under 24, stable oxygenation, normal mental status, you should switch to equivalent oral antibiotics. And we're really pushing for shorter durations now. The guidelines generally recommend a minimum of five days of total antibiotic therapy. But critically, the patient needs to have met those stability criteria and been a fee-brow for at least 48 to 72 hours before you actually stop the antibiotics. The shortest effect of course is the goal. Excellent summary of standard and MDR management. Now let's do that deep dive into section four, the atypical pathogens. We know we cover them empirically with the macrolite or doxycycline, but recognizing when they might actually be the cause can sometimes influence our thinking, especially if things aren't going as expected. Who is at higher risk for these atypicals? Let's start with Michael Plasma and chlamydia pneumonia. These tend to be more common in younger adults, say under 50 or 60, often healthier individuals without a lot of chronic underlying longer heart disease. We also think about the more in outbreak settings, you know, college dorms, military barracks, because Michael Plasma in particular can spread easily person to person. Okay, and Legionella has a very different risk profile, linked more to environmental exposure. Completely different. Legionella risk is all about exposure to contaminated water aerosols. Think cooling towers on large buildings, ventilation systems, humidifiers, decorative fountains, even whirlpool spas or sometimes hospital water systems. The exposure usually happens within the two weeks before symptoms start. The patients who tend to get sick are often older adults, current or former heavy smokers, and those with chronic lung conditions like COPD or people who are immune suppressed. Asking about potential water exposures is really key if Legionella is on your radar. And if you suspect it, you need specific testing, like the urine antigen test. Yes. The Legionella pneumophilus serogroup one urine antigen test is crucial if you have clinical or epidemiological suspicion. It's rapid and reasonably sensitive for the most common type. Given how severe Legionnaires disease can be, testing is important. Now, the challenge, as you mentioned, is that clinically atypical pneumonia can look a lot like typical bacterial pneumonia. No single sign or symptom is foolproof. But are there patterns or constellations of features that might make us lean towards an atypical cause? There are definitely suggestive clues, even if they aren't definitive. For mycoplasma or chlamydia, you might see a more gradual onset, maybe over several days to a week. The cough is often really prominent, but typically dry and hacking, not producing much sputum. Fever might be lower grade compared to classic pneumococcus. And what about symptoms outside the lungs? That's often a key differentiator. Patients might have significant extra pulmonary symptoms. A really bad headache, sometimes mimicking meningitis, severe muscle aches, myelages, maybe a rash, like airy-thema-multiform with mycoplasma, sometimes even things like mild hemolytic anemia. On basic labs, the white count might be normal or only slightly elevated, maybe with more lymphocytes than neutrophils. And inflammatory markers like CRP or pro-calcitonin might be less dramatically elevated than you'd expect, for how sick the patient seems systemically. So that mismatched prominent systemic symptoms, but maybe less impressive focal long signs or inflammatory markers, is kind of a hint for mycoplasma or chlamydia. How does Legionella typically present? It sounds much more severe usually. Oh, Legionella is often traumatic and severe, frequently looking like formin and sepsis right from the start. Patients typically have high fever, often over 40 degrees C, 104 degrees RF, and feels systemically very unwell, very quickly. What are the distinguishing features beyond just the severity? The most classic clues are the associated gastrointestinal symptoms. Water diaries are very common, maybe in up to 50% of cases, nausea and vomiting are also frequent. These GI symptoms are much less common with typical bacterial CAP or other atypicals. And the lab findings can be quite specific too. Very suggestive yes. Look for significant hyponutremia, low sodium, often quite profound, thought to be due to SIDH. You might see relative bradycardia, where the heart rate is slower than you'd expect for such a high fever. Elevated liver function tests are common, reflecting liver involvement, and rapid progression to kidney injury or confusion and cephalopathy is also characteristic. So Legionella often presents as a severe multi-system illness with those specific GI and electrolyte abnormalities, very different pattern than microplasma. Since the clinical picture can overlap, imaging often plays a role, especially early on. Are there characteristic radiological findings that might suggest an atypical pathogen is at play, particularly on CT scans? Yes. The imaging can offer clues, reflecting the underlying pathology. Atypicals often cause more inflammation in the interstitium, the lungs scaffolding in the small airways, bronchiolatus, rather than filling the air sacs alveoli with dense pus, like typical bacteria often do. So, for microplasma and chlamydia, what does that interstitial pattern look like on X-ray or CT? On a chest X-ray, you might see patchy infiltrates, often bilateral. Maybe described as reticular nodular, meaning a network of lines and small dots. They often favor the lower lobes. On a high-resolution CT scan, you get more detail. You might see central lobular nodules, which are tiny nodules clustered around the small airways, indicating bronchiolitis. You often see widespread, hazy ground glass opacities representing inflammation in the air spaces or interstitium. Thickening of the walls of the airways and blood vessels, bronchovascular bundles, is also common. Importantly, large pleural effusions are rare with these two. Okay, so a more diffused patchy, nonjular ground glass appearance suggests microplasma or chlamydia. How does Legionella look on imaging, given it causes such severe disease? Is it also interstitial? Legionella can be tricky, because it often progresses very rapidly. It might start as patchy ground glass opacities, similar to other atypicals or viruses. But it tends to quickly coalesce into denser airspace consolidation, which can become quite extensive involving multiple lobes, either unilaterally or bilaterally. So consolidation is a major feature, unlike microplasma. CT scans often show areas of ground glass opacity, surrounding the denser consolidation. Small pleural effusions can sometimes be seen, though large ones are uncommon. The real radiological hallmark is often the rapidity and extent of the consolidation developing over the first day or two. So to be clear, imaging alone can't definitively diagnose an atypical pneumonia? Absolutely not. There's way too much overlap between different causes. But seeing those patterns, the diffuse, particular nodular or ground glass changes, perhaps suggesting microplasma chlamydia or the rapidly progressive consolidation, perhaps with ground glass hints, suggesting Legionella, especially when combined with the right clinical context. Like the patient's age, exposures, GI symptoms, labs, it definitely helps support the continued need for empiric atypical coverage until you have more definitive information or the patient recovers. Right. It reinforces the rationale behind the standard combination therapy. Okay, let's wrap up by summarizing the key takeaways for clinicians managing hospitalized CACI today. Okay, first big takeaway. The pathogen landscape is shifted. Viruses are major players. This means we absolutely must test for both influenza and COVID-19 and hospitalized CAP patients when these viruses are circulating. It directly impacts treatment and infection control. Second point, the standard empiric therapy for most non-severe, non-MDR risk patients remains a beta-lactome plus a macrolide, like a zythromycin. And remember, that macrolate isn't just for atypical coverage. It likely offers important immunomodulatory benefits, especially in severe CIP. Doxycycline is an alternative, but maybe without that same edge. Third, rigorous risk stratification for MDR pathogens, MRSA and pseudomonas is essential, especially in severe CIP or patients with specific risk factors. This guides the need for broader empiric coverage, like vancomycin lanyzolid or pipped as a subfipine. And crucially, be aware of and try to mitigate the increase A.K.I. risk when combining vancomycin and pipersilent-tozobactome, perhaps by choosing alternatives if possible. And finally, fourth takeaway. While empiric atypical coverage is standard, stay alert for clinical and radiological clues suggesting atypical pathogens. Recognize the distinct patterns, the environmental exposure, GI symptoms, and hyponutremia pointing towards legionella, or the younger age, gradual onset, dry cough, headache, and systemic symptoms, perhaps hinting at microplasma or chlamydia. These patterns, along with suggestive imaging, like reticulonodular or ground glass findings, help reinforce why that atypical coverage is needed initially. Exactly. Those are the core evidence-based adjustments we need to make in our daily practice for managing CAP effectively and safely. Which brings us to our final thought for you, the listener. We spend all this time talking about diagnosing and treating CAP once it happens the antibiotics, the risk scores, the ICU criteria. But, you know, despite all these advances in acute management, maybe the most impactful thing we can do to reduce the overall burden of this disease lies elsewhere. Absolutely. It's prevention. As physicians caring for these patients, perhaps the single most important non-pharmacologic intervention we can make, one that definitely affects outcomes, is ensuring our patients are up to date on their vaccinations. Taking that moment to check pneumococcal influenza and COVID-19 vaccine status for every patient, especially those at risk or being admitted, and getting them vaccinated if needed, even during their hospital stay, if appropriate, that's fundamental stewardship. Focusing on preventing the next case is ultimately the best strategy for tackling CAP.